Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells

20 Feb 2016

Abstract excerpt

Nutlin3a is a small-molecule antagonist of MDM2 that promotes non-genotoxic activation of p53 through p53 protein stabilization and transactivation of p53 target genes. Nutlin3a is the forerunner of a class of cancer therapeutics that have reached clinical trials. Using transgenic and gene-targeted mouse models lacking the critical p53 target genes, p21, Puma, and Noxa, we found that only loss of PUMA conferred...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Retinoids in leukemia and cellular processes
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26904937
DOI: 10.1016/j.celrep.2016.01.059

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma CellsPMID 26904937Read ↗

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.Semantic proximity Read ↗

MNT loss in MYC-driven B lymphoma cells enhances apoptosis, inhibits proliferation and increases sensitivity to cancer drugsSemantic proximity Read ↗

Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3Semantic proximity Read ↗

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).Semantic proximity Read ↗

Small Molecule Inhibition of HDM2 Leads to p53-Mediated Cell Death in Retinoblastoma CellsSemantic proximity Read ↗

Interruption of p53-MDM2 Interaction by Nutlin-3a in Human Lymphoma Cell Models Initiates a Cell-Dependent Global Effect on Transcriptome and Proteome LevelSemantic proximity Read ↗

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myelomaSemantic proximity Read ↗

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapySemantic proximity Read ↗

Recent Advances in the Therapeutic Perspectives of Nutlin-3Semantic proximity Read ↗

Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITASemantic proximity Read ↗

MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cellsSemantic proximity Read ↗

Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.